Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab + docetaxel versus placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer
2007-002997-72Phase 3Terminated
- Sponsor
- Roche
- Start
- Nov 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pertuzumab + trastuzumab + docetaxel with Placebo + trastuzumab + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Nov 2007; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-002997-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002997-72.